摘要
目的分析非小细胞肺癌患者血小板活化标志物CD62P、CD63及血小板参数作为肺癌肿瘤标志物的可行性,为其作为靶分子治疗肺癌提供一定的依据。方法选择2014年1月至2015年1月该院收治的62例确诊为非小细胞肺癌初治患者为肺癌组,同期45例肺良性病变患者为肺良性病变组,38例体检健康者为健康对照组。采用抗血小板膜糖蛋白的单克隆抗体分子探针,经免疫荧光标记,用流式细胞术检测单个或血小板亚群膜糖蛋白的表达,同时采用血细胞分析仪联合检测。结果 (1)肺癌患者CD62P、CD63、血小板计数(PLT),平均血小板体积(MPV),血小板比容(PCT)与肺良性病变组及健康对照组间比较,差异有统计学意义(P<0.05);血小板分布宽度(PDW)差异无统计学意义(P>0.05)。(2)肺腺癌与肺鳞癌的CD62P、CD63水平比较,差异有统计学意义(P<0.05);CD62P、CD63水平与肿瘤分化程度、患者性别、年龄均无关(P>0.05)。(3)CD62P和CD63的表达水平随TNM分期的增加而升高,Ⅲ+Ⅳ期与Ⅰ+Ⅱ期比较,差异有统计学意义(P<0.05)。CD62P和CD63表达与有无淋巴结转移和有无远处转移有密切关系(P<0.05)。结论肺癌患者血小板活化标志物CD62P、CD63和血小板参数对肺癌的发生、发展、淋巴结转移和远处转移有一定关系,对其进行动态监测具有重要的临床价值。
Objective To analyze the feasibility of platelet activation marker CD62 P,CD63and platelet parameters as the tumor markers of lung cancer to provide a certain evidence for treating lung cancer with them as the targeted molecules.Methods A total of 62 cases of non-small cell lung cancer（NSCLC）treated in our hospital from January 2014 to January 2015 were selected as the lung cancer group,contemporaneous 45 cases of benign lung diseases were selected as the lung benign disease group and 38 individuals undergoing the physical examination as the control group.By using the platelet membrane glycoproteins monoclonal antibody molecules probe and immunofluorescence labeling,the flow cytometry was adopted to detect platelet membrane glycoproteins expression of single or PLT subgroup.At the same time,the hematology analyzer was used to detect the platelet parameters.Results（1）CD62P,CD63,PLT,MPV and PCT had statistical differences among the lung cancer group,lung benign disease group and normal control group（P0.05）;PDW had no statistical difference（P0.05）.（2）The expression of CD62 Pand CD63had statistical difference between lung adenocarcinoma and lung squamous carcinoma（P0.05）;the CD62 Pand CD63levels had no relation with the tumor differentiation degree,sex,age（P0.05）.（3）The CD62 P and CD63 expression levels were increased with TNM stage increase,the difference between the stageⅢ＋Ⅳand the stageⅠ＋Ⅱ was statistically significant（P0.05）.The CD62 Pand CD63expressions were closely related with lymph node metastasis and distant metastasis（P0.05）.Conclusion The platelet activation markers CD62 Pand CD63expression levels and platelet parameters have a certain relation with the occurrence,development,lymph node metastasis and distant metastasis of lung cancer.Their dynamic monitoring has an important clinical value.
出处
《检验医学与临床》
CAS
2016年第10期1319-1321,共3页
Laboratory Medicine and Clinic
基金
云南省教育厅科学研究基金资助项目(2013Y299)
